Micro
Aftermath
Archived
BHVNは肥満に関する研究への登録を完了しました
活動低下 — ストーリーの関連性が低下。
スコア
0.3
勢い
▲ 0.0
記事
5
情報源
2
値上がり・値下がり上位
| ティッカー | セクター | 変動 |
|---|---|---|
| Healthcare | +97.3% |
センチメントタイムライン
セクターパフォーマンス
株価パフォーマンス
イベントタイムライン
値上がり・値下がり上位
| ティッカー | セクター | 変動 |
|---|---|---|
| Healthcare | +97.3% |
🤖
AI概要
What happened: Biohaven Pharmaceuticals (BHVN) completed enrollment in a Phase 2 obesity study for its drug candidate, taldefgrobep alfa, on March 19, 2026. This follows analyst Ken Cacciatore from TD Cowen increasing his price target on BHVN from $15 to $30 on March 11, citing encouraging data from the company's Azetukalner program.
Market impact: The biopharmaceutical sector, particularly small-cap stocks, is affected. BHVN's stock surged on the news, driven by increased investor confidence in the company's pipeline. Hedge funds have also shown interest, with BHVN appearing in the top 7 small-cap healthcare stocks to buy.
What to watch next: Upcoming catalysts include the release of interim data from the taldefgrobep alfa obesity study in Q4 2026, regulatory decisions on Azetukalner, and BHVN's Q2 2026 earnings report, scheduled for mid-May.
Market impact: The biopharmaceutical sector, particularly small-cap stocks, is affected. BHVN's stock surged on the news, driven by increased investor confidence in the company's pipeline. Hedge funds have also shown interest, with BHVN appearing in the top 7 small-cap healthcare stocks to buy.
What to watch next: Upcoming catalysts include the release of interim data from the taldefgrobep alfa obesity study in Q4 2026, regulatory decisions on Azetukalner, and BHVN's Q2 2026 earnings report, scheduled for mid-May.
AI概要 (時点: 4月 15, 2026
タイムライン
初回検出3月 28, 2026
最終更新3月 28, 2026